Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis To Begin Long-Term Acomplia Cardio Safety Study By Fall

Executive Summary

Sanofi-Aventis will begin conducting a four-to-five year Acomplia (rimonabant) cardiovascular safety study by the fall, the company said

You may also be interested in...



Zimulti Loses On Weight Loss; Sanofi May Try Diabetes Route To Get Approval

If FDA concurs with the Endocrinologic and Metabolic Drugs Advisory Committee's negative opinion of the pending obesity indication for Zimulti (rimonabant), Sanofi-Aventis may have another attempt at bringing the drug to market for type 2 diabetes

Zimulti Loses On Weight Loss; Sanofi May Try Diabetes Route To Get Approval

If FDA concurs with the Endocrinologic and Metabolic Drugs Advisory Committee's negative opinion of the pending obesity indication for Zimulti (rimonabant), Sanofi-Aventis may have another attempt at bringing the drug to market for type 2 diabetes

Sanofi Feels The Weight Of FDA’s “Approvable” Letter For Rimonabant

FDA is not requesting additional clinical trials for Acomplia's weight loss indication, Sanofi-Aventis said Feb. 24 during its investors meeting in Paris

Related Content

Topics

UsernamePublicRestriction

Register

PS045580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel